NCT00807339

CyberKnife for Unresectable Renal Tumors

CyberKnife Stereotactic Radiation for Unresectable Renal Tumors/PhaseI Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Beth Israel Deaconess Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 95 Years
• Healthy volunteers: Not accepted

Summary

This is a dose escalation study using the CyberKnife radiotherapy device for small surgical or medically untreatable renal tumors. Patients with renal tumors 5cms or less in diameter will be accrued onto this study. The ability of CyberKnife to ablate these renal tumors and maintain renal function with dose escalation will be assessed.

Detailed description

The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The CyberKnife System delivers radiation using a precise targeting methodology allowing a focal treatment margin around the target, thus limiting the volume of adjacent tissue receiving high doses radiation. This in turn allows the delivery of high doses of radiation to the prostate over a short series of treatments.

Conditions

• Renal Cancer

Interventions

Type	Name	Description
RADIATION	Stereotactic radiation	Dose escalation three consecutive treatments
DEVICE	CyberKnife Robotic Radiosurgery System

Timeline

• Start date: 2006-03-01
• Primary completion: 2014-01-01
• Completion: 2014-08-20
• First posted: 2008-12-11
• Last updated: 2017-03-21

Locations

1 site across 1 country: United States